Global Markets for Enzyme Inhibitors -- Focus on Europe

The overall goal of this study is to provide a comprehensive understanding of the current and future characteristics of the global market for enzyme inhibitors.

This report explores present and future strategies within the market for enzyme inhibitors, which includes proton pump inhibitors (PPIs), protease inhibitors, reverse transcriptase inhibitors, kinase inhibitors, statins, aromatase inhibitors, phosphodiesterase type 5 (PDE5) inhibitors, neuraminidase inhibitors, and angiotensin-converting enzyme (ACE) inhibitors.  The improvements in the market and the setbacks and needs of the market are discussed in this report.  The comparisons, usage, and advantages and disadvantages of different types of enzyme inhibitors are also discussed in this report.

A detailed analysis of the enzyme inhibitors industry structure has been conducted.  Revenues are broken down by region.  Sales figures are estimated for the five-year forecast period of this report, from 2011 to 2016.

Applications for enzyme inhibitors are also discussed in the report, with emphasis on the usage of the inhibitors in therapeutic categories and various disease sectors.  The report also covers significant patents and their allotments in each category.

REPORT HIGHLIGHTS

• The global market for enzyme inhibitors was valued at $104.4 billion in 2010 and reached nearly $104.6 billion in 2011. This market is expected to rise at a compound annual growth rate (CAGR) of 4% and reach nearly $127.4 billion by 2016.
• The European market for enzyme inhibitors was $32 billion in 2010, which rose to $32.4 billion in 2011. This sector is expected to rise at a CAGR of 3.6% and reach nearly $38.7 billion by 2016.
• European sales of kinase inhibitors were $9.2 billion in 2010 and $9.4 billion in 2011. This segment is expected to grow at a CAGR of 4.4% and reach $11.6 billion by 2016.